Janus Henderson Group’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.49M Buy
206,554
+5,649
+3% +$49.2K ﹤0.01% 1587
2026
Q2
$2.09M Buy
+200,905
New +$1.49M ﹤0.01% 1441

Other funds holding RNAC

Janus Henderson Group's RNAC Position: Q3 2026 in Review

Janus Henderson Group increased its Cartesian Therapeutics (RNAC) stake by 2.8% in Q3 2026, buying an estimated $49.2K and bringing the position to 206,554 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

Janus Henderson Group first reported a position in RNAC in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.09M in Q2 2026. 100 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Janus Henderson Group held 206,554 shares of Cartesian Therapeutics worth $1.49M as of Q3 2026.
  • Janus Henderson Group bought 5,649 Cartesian Therapeutics shares in Q3 2026, an estimated $49.2K.
  • Cartesian Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q3 2026, its #1587 holding.
  • Janus Henderson Group first reported a position in Cartesian Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Janus Henderson Group's Cartesian Therapeutics position peaked at $2.09M in Q2 2026.
  • 100 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.